About this trial
Atrial fibrillation (AF) is a common arrhythmia, especially in the elderly, and can lead to severe complications like stroke and heart failure. In China, AF affects approximately 20 million adults, and its prevalence is expected to rise due to aging \[1, 2\]. Catheter ablation has become a first-line treatment for AF, with pulsed field ablation (PFA) gaining attention due to its tissue selectivity and non-thermal ablation properties \[3-8\]. PFA uses high-voltage electric fields to create cell membrane perforations, leading to permanent tissue damage and effective arrhythmia treatment \[6-8\].
Recent studies have shown that PFA is highly effective and safe. For example, the EU-PORIA study reported a 99.96% pulmonary vein isolation (PVI) rate with a 3.6% complication rate \[9, 10\], while the ADVENT study demonstrated similar efficacy to thermal ablation but with shorter procedure times \[12\]. However, current PFA systems often lack integration with 3D mapping systems, limiting their application in complex cases and increasing reliance on fluoroscopy \[13, 14\].
In China, domestic PFA technology is rapidly evolving, with a focus on expanding indications and integrating 3D techniques \[19, 20\]. The investigators have conducted preliminary studies on the feasibility and safety of domestic PFA in persistent AF treatment \[21\]. To further advance PFA, larger-scale clinical studies are needed to optimize procedural workflows and reduce complications.
This study aims to enroll 430 participants through a single-center, single-arm approach. By following up for one year, the investigators will optimize the PFA procedure under 3D guidance to enhance success rates and safety. This will support the clinical promotion of PFA technology and provide valuable data for the development of domestic PFA devices.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18 years or older, regardless of gender.
Patients with paroxysmal atrial fibrillation scheduled for catheter ablation.
Willing and able to comply with all follow-up requirements and agree to participate in this study.
Disqualifiers
Previous left atrial catheter ablation.
Left ventricular ejection fraction (LVEF) < 35%.
Left atrial diameter (assessed by echocardiography) > 55 mm.
Presence of definite thrombus in the left atrium or any other cardiac chamber detected before surgery.
Trial population
Patients with paroxysmal atrial fibrillation scheduled for radiofrequency ablation.
Trial design
Cohort
Prospective
Treatments tested in this trial
pulsed field ablation
Procedure/SurgeryPulsed electric fields refer to the generation of high-voltage electric fields with pulse widths ranging from milliseconds to microseconds or even nanoseconds. These fields release extremely high energy in a very short time, creating a large number of irreversible micropores in the cell membrane and even intracellular organelles such as the endoplasmic reticulum, mitochondria, and nucleus. This ultimately leads to apoptosis of the diseased cells, achieving the desired therapeutic effect. By inserting a pulsed ablation catheter into the patient's body and reaching the target lesion, the pulsed energy is delivered to the ablation catheter via a cardiac pulsed field ablation device, thereby achieving the therapeutic goal of pulsed field ablation.
Treatment groups
Trial outcomes
Primary outcomes
12-Month Postoperative Treatment Success Rate
Definition of 12-Month Postoperative Treatment Success: No recurrence of atrial arrhythmias (atrial fibrillation, atrial tachycardia, or unexplained atrial flutter) lasting ≥30 seconds from 3 months to 12 months postoperatively, and no occurrence of any of the following failure modes: immediate procedural failure, repeat ablation failure (more than 1 repeat ablation during the blanking period, or any repeat ablation outside the blanking period), antiarrhythmic drug (AAD) failure (use of new Class I/III AADs for treatment of atrial fibrillation, atrial tachycardia, or unexplained atrial flutter, or increased dosage of previously failed Class I/III AADs), persistent atrial fibrillation/atrial tachycardia/atrial flutter documented by standard 12-lead ECG, or failure of electrical cardioversion. Calculation: 12-Month Postoperative Treatment Success Rate = (Number of patients with treatment success at 12 months / Total number of patients completing 12-month follow-up) × 100%
Secondary outcomes
Immediate Procedural Success Rate
Definition of Immediate Procedural Success: Achievement of complete pulmonary vein isolation and superior vena cava isolation after ablation. Calculation: Immediate Procedural Success Rate = (Number of patients with immediate procedural success / Total number of patients undergoing the procedure) × 100%
Success Rate of No Recurrence of Atrial Arrhythmias (≥30 seconds) Without Class I/III AADs from 3 Months to 12 Months Postoperatively
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: